Omer Anis

Omer Anis


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2021 in Molecules
Verified
Journal Article
Open access
PDF file
OAOmer Anis
Omer Anis
VCVinayaka Ajjampura Chandrashekarappa
Vinayaka Ajjampura Chandrashekarappa
NSNurit Shalev
Nurit Shalev
Dvory NamdarDvory Namdar
Dvory Namdar
SNSTALIN NADARAJAN
STALIN NADARAJAN
Hinanit KoltaiHinanit Koltai
Hinanit Koltai
Cannabis sativa contains more than 500 constituents, yet the anticancer properties of the vast majority of cannabis compounds remains unknown. We aimed to identify cannabis compounds and their combinations presenting cytotoxicity against bladder urothelial carcinoma (UC), the most common urinary system cancer. An XTT assay was used to determine cytotoxic activity of C. sativa extracts on T24 and HBT-9 cell lines. Extract chemical content was identified by high-performance liquid chromatography (HPLC). Fluorescence-activated cell sorting (FACS) was used to determine apoptosis and cell cycle, using stained F-actin and nuclei. Scratch and transwell assays were used to determine cell migration and invasion, respectively. Gene expression was determined by quantitative Polymerase chain reaction (PCR). The most active decarboxylated extract fraction (F7) of high-cannabidiol (CBD) C. sativa was found to contain cannabichromene (CBC) and Δ9-tetrahydrocannabinol (THC). Synergistic interaction was demonstrated between CBC + THC whereas cannabinoid receptor (CB) type 1 and type 2 inverse agonists reduced cytotoxic activity. Treatments with CBC + THC or CBD led to cell cycle arrest and cell apoptosis. CBC + THC or CBD treatments inhibited cell migration and affected F-actin integrity. Identification of active plant ingredients (API) from cannabis that induce apoptosis and affect cell migration in UC cell lines forms a basis for pre-clinical trials for UC treatment.

20 October 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Dvory NamdarDvory Namdar
Dvory Namdar
OAOmer Anis
Omer Anis
PPPatrick Poulin
Patrick Poulin
Hinanit KoltaiHinanit Koltai
Hinanit Koltai
Despite the surge in cannabis chemistry research and its biological and medical activity, only a few cannabis-based pharmaceutical-grade drugs have been developed and marketed to date. Not many of these drugs are Food and Drug Administration (FDA)-approved, and some are still going through regulation processes. Active compounds including cannabinergic compounds (i.e., molecules targeted to modulate the endocannabinoid system) or phytocannabinoid analogues (cannabinoids produced by the plant) may be developed into single-molecule drugs. However, since in many cases treatment with whole-plant extract (whether as a solvent extraction, galenic preparation, or crude oil) is preferred over treatment with a single purified molecule, some more recently developed cannabis-derived drugs contain several molecules. Different combinations of active plant ingredients (API) from cannabis with proven synergies may be identified and developed as drugs to treat different medical conditions. However, possible negative effects between cannabis compounds should also be considered, as well as the effect of the cannabis treatment on the endocannabinoid system. FDA registration of single, few, or multiple molecules as drugs is a challenging process, and certain considerations that should be reviewed in this process, including issues of drug–drug interactions, are also discussed here.

1 January 2020 in Urology
Verified
Journal Article
Closed access
OAOmer Anis
Omer Anis
URUri Rimon
Uri Rimon
JRJacob Ramon
Jacob Ramon
BKBoris Khaitovich
Boris Khaitovich
DZDorit E. Zilberman
Dorit E. Zilberman
ZDZohar A. Dotan
Zohar A. Dotan

4 June 2024 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
OAOmer Anis
Omer Anis
ACArnon Dov Cohen
Arnon Dov Cohen
SAShachar Aharony
Shachar Aharony
NKNoam D. Kitrey
Noam D. Kitrey
IDIdit Dotan
Idit Dotan
SYShlomit Yaron
Shlomit Yaron

13 April 2023 in Autoimmunity Reviews
Verified
Journal Article
Closed access
OAOmer Anis
Omer Anis
DYDavid Yogev
David Yogev
ADArad Dotan
Arad Dotan
ATAvishai M. Tsur
Avishai M. Tsur
PDPaula David
Paula David
YSYehuda Shoenfeld
Yehuda Shoenfeld

31 March 2025 in International Neurourology Journal
Verified
Journal Article
Open access
PDF file
TTTyler Trump
Tyler Trump
OAOmer Anis
Omer Anis
HGHoward B. Goldman
Howard B. Goldman
PCPo-Ming Chow
Po-Ming Chow
Purpose: Urgency urinary incontinence (UUI) is a common finding in patients with a history of stroke or cerebrovascular accident (CVA). UUI is associated with impaired quality of life as well as increased morbidity, mortality, and need for institutionalization. Medical therapy is often limited by side effects and/or cost prohibitiveness. As a result, third-line therapy is often implemented. The objective is to determine the efficacy of sacral neuromodulation (SNM) and onabotulinum toxin (BTX) in the management of post-CVA UUI.Methods: Retrospective analysis was performed to identify patients with post-CVA UUI who underwent SNM or BTX at a large academic medical center. The primary outcome was patient symptom response to third-line therapy. Treatment response was determined using the global response assessment scale. Patients reporting >50% improvement were categorized as having significant response. Secondary endpoints were proportion of patients achieving total dry and duration of therapy for those achieving significant response.Results: One hundred seventy-seven patients were identified (95 BTX, 82 SNM). Patients in the BTX group were older (71.9 years vs. 67.4 years, P=0.02) with otherwise similar demographics. Rate of symptom improvement to >50% of baseline was similar between the groups (66% of BTX, 61% of SNM, P=0.46) as was rate of patients experiencing total dryness (24% of BTX, 16% of SNM, P=0.17). Among patients achieving significant improvement there was no difference in continuation of therapy between the BTX and SNM groups. Younger age was identified as a predictor of >50% symptom improvement (odds ratio, 0.96; P=0.04) and treatment discontinuation (hazard ratio, 0.97; P=0.04) in SNM. Most common adverse events were urinary tract infection in BTX (11%) and pain in SNM (4%).Conclusions: BTX and SNM show roughly equal efficacy in the management of post-CVA UUI with nearly two-thirds of patients achieving significant benefit.